How Can We Apply Guidelines in the Rapidly Changing MS Treatment Landscape?

Credit Types
AAPA: 1.00
ACPE: 1.00
CME: 1.00
CNE: 1.00
CNE – Pharmacology: 1.00
Letter of Completion: 1.00

Management of multiple sclerosis (MS) occurs in a rapidly changing environment in which decisions must be made using the latest available data and insights. This webinar serves as a review and update to the CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis, published in early 2019. These guidelines were developed based on a consensus conference independently convened in 2018 by the Consortium of Multiple Sclerosis Centers (CMSC) among a group of MS experts. As the year 2019 comes to a close, program chairs Corey Ford and Sarah Morrow will review key points of the guideline states, focusing in on current “hot topics” in MS management and that latest updates that arose throughout the year.

Faculty
DMT Consensus Committee Program Chairs
Corey C. Ford, MD, PhD
Professor of Neurology
Senior Associate Dean for Research
Director, MS Specialty Clinic
University of New Mexico Health Sciences Center
Albuquerque, NM

Sarah A. Morrow, MD, MS, FRCPC
Associate Professor
Clinical Neurological Sciences
Western University
Director, London Multiple Sclerosis Clinic
London, Ontario
Canada

Distributed by Delaware Media Group
PO Box 937, Glen Rock, NJ 07452-0937
Tel: 201-612-7676
Fax: 201-612-8282

Medical Writer/Editor
Katherine Wandersee

Art Director
James Ticchio

Release Date: December 2, 2019
Valid for Credit Through: December 31, 2020

Learning Objectives
Identify frameworks for therapeutic decision-making for disease-modifying treatment of relapsing-remitting, primary progressive, aggressive-onset, and pediatric multiple sclerosis.

Determine rationale for switching therapies for patients with MS to optimize disease management based on individual efficacy, safety, and tolerability needs.

Discuss recent changes and ongoing challenges associated with MS treatment including decisions about starting, stopping, and escalating therapy.

Target Audience:
This activity is designed to meet the educational needs of physicians, nurses, advanced practice clinicians, and pharmacists who manage patients with multiple sclerosis (MS).

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit
The CMSC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Credit
The CMSC designates this enduring material for 1.00 contact hours (1.0 in the area of pharmacology).

Pharmacists
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who (1) participant in the activity, (2) pass the post-test; and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-007-H01-P. This is a knowledge-based activity.

PAs
The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

The CMSC designates this enduring material for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Certificate of Participation for Other Healthcare Professionals
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.

Support Acknowledgement
This webinar is supported by educational grants from Avanir Pharmaceuticals, Biogen, EMD Serono, and Sanofi Genzyme.

Disclosure Statements:
Corey C. Ford, MD, PhD has received consulting fees from Novartis, Teva, and TG Therapeutics.

Sarah Morrow, MD, MS has received consulting fees from Biogen, EMD Serono, Novartis, Roche, and Sanofi Genzyme.

Reviewer/Nurse Planner
June Halper, MSN, APN-C, MSCN, FAAN served as Planner for this activity and has disclosed no relevant financial relationships.

The following planners and managers have disclosed no relevant financial relationships: Joseph J. D’Onofrio, Frank Marino, Katherine Wandersee.

Method of Participation:
Follow these steps to earn CME/CNE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or during the live webinar program.
  3. Complete the post test and evaluation.

Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation.

There is no fee to participate in this activity.

If you have any questions about this CME/CNE activity, please contact the CMSC at education@mscare.org or 201-487-1050.

How to Receive Credit
To successfully complete this activity, the participant must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, complete the evaluation and claim credit.

  1. To complete the evaluation and claim credit, please click on the To Claim Credit button below or go to: highmarksce.com/mscare/.
  2. Log in with your user name and password*, or create a new account.
  3. Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.

*If you do forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.

Disclosure of Unlabeled Use:
This CME/CNE activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Delaware Media Group, and the supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, Delaware Media Group, or the supporters.

Privacy Policy:
Copyright © 2019, Delaware Media Group, Inc. All rights reserved. None of the contents of this webinar program may be reproduced in any form without prior written permission. The opinions expressed in this program are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or the supporters.